Computer-aided drug discovery for pathway and genetic diseases

Selecting drug targets in pathway and genetic diseases (e.g., cancer) is a difficult problem facing the medical field and pharmaceutical industry. Because of the complex interconnections and feedback found in biological pathways, it is difficult to understand the potential effects of targeting certain portions of the network. The pharmaceutical industry has avoided novel targets for drugs, largely because of the increased risk in developing such treatments. This necessitates the need for systems biology methods which can help mitigate some of the risks of identifying novel targets and also suggest further experiments to validate them. The primary goal of this paper is to introduce a mathematical framework for solving such problems, that is amenable to computational or mathematical study. The secondary goal is to suggest methods for solving problems posed in this framework. One of these methods is a heuristic which is designed to allow its computations to scale up to much bigger examples and pathways than presented here.

[1]  Margaret Ashcroft,et al.  Regulation of p53 stability , 1999, Oncogene.

[2]  Van,et al.  L2-Gain Analysis of Nonlinear Systems and Nonlinear State Feedback H∞ Control , 2004 .

[3]  Pedro de Atauri,et al.  Metabolic control analysis in drug discovery and disease , 2002, Nature Biotechnology.

[4]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[5]  T. Léveillard,et al.  The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter* , 1997, The Journal of Biological Chemistry.

[6]  E. Dougherty,et al.  CONTROL OF STATIONARY BEHAVIOR IN PROBABILISTIC BOOLEAN NETWORKS BY MEANS OF STRUCTURAL INTERVENTION , 2002 .

[7]  Nicholas Boyd,et al.  Graph-theoretic topological control of biological genetic networks , 2009, 2009 American Control Conference.

[8]  Stephanie Carter,et al.  Regulation of p 53 stability and function by the deubiquitinating enzyme USP 42 , 2011 .

[9]  Bohdan Wasylyk,et al.  p53-independent functions of MDM2. , 2003, Molecular cancer research : MCR.

[10]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[11]  M. Takagi,et al.  Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin , 2005, Cell.

[12]  A. Barabasi,et al.  Predicting synthetic rescues in metabolic networks , 2008, Molecular systems biology.

[13]  Ashish Choudhury,et al.  Control approaches for probabilistic gene regulatory networks - What approaches have been developed for addreassinig the issue of intervention? , 2007, IEEE Signal Processing Magazine.

[14]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[15]  A. Schaft.  L/sub 2/-gain analysis of nonlinear systems and nonlinear state-feedback H/sub infinity / control , 1992 .

[16]  Claire J. Tomlin,et al.  Monotone Piecewise Affine Systems , 2009, IEEE Transactions on Automatic Control.

[17]  Stephen P. Boyd,et al.  Linear Matrix Inequalities in Systems and Control Theory , 1994 .

[18]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[19]  Claire J. Tomlin,et al.  Topology based control of biological genetic networks , 2008, 2008 47th IEEE Conference on Decision and Control.

[20]  Nagasuma R. Chandra,et al.  Flux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs , 2005, PLoS Comput. Biol..

[21]  George J. Pappas,et al.  Metabolic networks analysis using convex optimization , 2008, 2008 47th IEEE Conference on Decision and Control.

[22]  Kenneth J. Kauffman,et al.  Advances in flux balance analysis. , 2003, Current opinion in biotechnology.